A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms DEFINE
- Sponsors Celgene Corporation
- 23 Jan 2018 This trial has been discontinued in Netherlands according to European Clinical Trials Database record.
- 15 Jan 2018 This trial has been Discontinued in Poland according to European Clinical Trials Database record.
- 09 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.